Focal Epilepsy

Study:  VRX-RET-E22-301

Purpose of Study:  To explore the efficacy and safety of Retigabine (1200 mg/day) used as Adjunctive Therapy in Refractory Epilepsy patients with partial-onset seizures.

Inclusion Criteria:

• Age 18-75 years
• Diagnosis of refractory epilepsy with simple partial or complex partial seizures with or without secondary generalization
• Within the past 10 years, patients having 1 EEG or video EEG and 1 MRI or CT with results consistent with partial-onset seizures
• Good verbal and writing skills
• Parent or legal guardian (if applicable) consent

Exclusion Criteria:

• History of alcohol or drug abuse within the past year
• Evidence of progressive CNS disease (lupus, tumors, MS, Alzheimer's)
• History of malignancy within the past 2 years (exception: basal cell carcinoma)
• Pregnant or breastfeeding
• Received retigabine in previous study
• Treated with felbamate or vigabatrin in the past 6 months
• History of primary generalized seizures

If you qualify, all study related care is provided at no charge including:

• Study visits and study related procedures/tests
• Laboratory tests
• Study medication
• Financial compensation for time/travel expenses

Inclusion/Exclusion Criteria Must Be Met